ZyVersa Therapeutics, Inc. (ZVSA)

5.28 -0.32 (-5.71%) At close: 04:00PM EDT

ZyVersa Therapeutics, Inc.

2200 N. Commerce Parkway
Suite 208
Weston, FL 33326
United States
754 231 1688
https://www.zyversa.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 7

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stephen C. Glover	Co-Founder, Chairman, CEO & President	775k	N/A	1960
Mr. Peter Wolfe	CFO & Secretary	477.5k	N/A	1968
Ms. Karen A. Cashmere	Chief Commercial Officer	410k	N/A	1952
Ms. Melda Uzbil O'connell	Senior Vice President of Corporate Development	N/A	N/A	N/A
Dr. Pablo A. Guzman FACC, M.D.	Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board	N/A	N/A	1950

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

Corporate governance

ZyVersa Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.